Dyadic International (DYAI) vs SeaStar Medical (ICU)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
SeaStar Medical (ICU) has outperformed Dyadic International (DYAI) over the past year, losing 47.0% versus a loss of 60.7%. Over five years, DYAI leads with a -90.8% price change compared with -99.9% for ICU. SeaStar Medical is the larger company by market cap ($18.5 million vs $17.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DYAI | ICU |
|---|---|---|
| Share price | $0.447 | $3.51 |
| Market cap | $17.91M | $18.47M |
| 1-day change | +0.59% | +0.57% |
| YTD return | -52.72% | +45.42% |
| 1-year return | -60.67% | -47.04% |
| 5-year return | -90.84% | -99.86% |
| EPS (TTM) | $-0.23 | $-2.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.60 | $7.35 |
| 52-week low | $0.34 | $2.07 |
| Distance from 52-week high | -72.06% | -52.25% |
| Analyst consensus | none | none |
| Avg. price target upside | +1130.43% | +184.91% |
| Average volume | 201.91K | 99.80K |
| Shares outstanding | 40.06M | 5.26M |
| Employees | 5 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ICU has outperformed DYAI by 13.6 percentage points over the past year.
About Dyadic International
DYAI stock →Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
About SeaStar Medical
ICU stock →SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis.
Health Care · Medical/Dental Instruments · 18 employees
DYAI vs ICU FAQ
Which is bigger, Dyadic International or SeaStar Medical?
SeaStar Medical (ICU) is larger, with a market capitalization of $18.47M compared with $17.91M for Dyadic International (DYAI).
Which stock has performed better over the past year, DYAI or ICU?
ICU returned -47.04% over the past 12 months, compared with -60.67% for DYAI (price return, excluding dividends). Past performance does not predict future results.
Are Dyadic International and SeaStar Medical in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Dyadic International and Medical/Dental Instruments for SeaStar Medical.